Xeno Biosciences is focused on developing innovative treatments for obesity and related metabolic diseases. Their lead investigational product, XEN-101, is a first-in-class oral formulation designed to induce weight loss by mimicking the microbiome alterations typically associated with gastric bypass surgery. This novel approach has shown significant weight loss effects in both animal models and human studies, with a favorable safety profile. The company is currently preparing to evaluate XEN-101 in a Phase I clinical trial, aiming to provide a new therapeutic option for patients suffering from obesity, a condition that is increasingly recognized as a complex neurological disease with serious health implications.

The company is led by a team of experienced professionals with extensive backgrounds in clinical research and biopharmaceuticals. Their leadership includes experts in obesity research and management, who are dedicated to advancing the understanding and treatment of obesity through evidence-based approaches. Xeno Biosciences is committed to delivering transformational therapies that address the multifactorial nature of obesity, thereby improving the quality of life for patients affected by this chronic condition. The company’s strategic focus on innovative drug development positions it as a promising player in the field of metabolic disease treatment.

United States

Xeno Biosciences is pioneering a novel class of treatments targeting the human gut microbiome to address unmet needs in metabolic diseases.

Xeno Biosciences

Company Details